Table 1.

Key features of randomized controlled trials included in the meta‐analysis

	Year	Device	Number of patients			Major parameters guiding management		Type of monitoring	Follow‐up
			Overall	Guided management	Control	Guided management	Control
CHAMPION 11	2016	CardioMEMS HF System	550	270	280	Pulmonary artery pressures	Non‐invasive telemonitoring	Haemodynamic	18 months
COMPASS‐HF 27	2008	Chronicle ICHM	274	134	140	Pulmonary artery and right ventricular diastolic pressures	Non‐invasive telemonitoring	Haemodynamic	6 months
CONNECT‐OptiVol 14	2015	ICD/CRT	176	87	89	Intrathoracic impedance	Usual care	Impedance	15 months
GUIDE‐HF 12	2021	CardioMEMS HF System	1000	497	503	Pulmonary artery pressures	Non‐invasive telemonitoring	Haemodynamic	12 months
LIMIT‐CHF 13	2016	ICD/CRT	80	41	39	Intrathoracic impedance	Usual care	Impedance	12 months
MORE‐CARE 29	2017	CRT	865	437	428	Intrathoracic impedance and atrial tachyarrhythmia	Usual care	Impedance	24 months
OptiLink HF 30	2016	ICD/CRT	1002	505	497	Intrathoracic impedance	Usual care with device data accessible in the clinic	Impedance	23 months
REDUCEhf 31	2011	Chronicle ICD	400	202	198	Pulmonary artery and right ventricular diastolic pressures	Non‐invasive telemonitoring	Haemodynamic	12 months

CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; ICHM, implantable continuous haemodynamic monitor.